Antiobjetivo (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Antiobjetivo" in Spanish language version.

refsWebsite

Global rank Spanish rank

11nih.gov

4^th place

11doi.org

2^nd place

1federalregister.gov

2,474^th place

9,675^th place

doi.org (Global: 2^nd place; Spanish: 2^nd place)

dx.doi.org

Klabunde, T.; Evers, A. (2005). «GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects». ChemBioChem: A European Journal of Chemical Biology 6 (5): 876-889. PMID 15791686. doi:10.1002/cbic.200400369.
Price, D.; Blagg, J.; Jones, L.; Greene, N.; Wager, T. (2009). «Physicochemical drug properties associated with in vivo toxicological outcomes: a review». Expert Opinion on Drug Metabolism & Toxicology 5 (8): 921-931. PMID 19519283. doi:10.1517/17425250903042318.
De Ponti, F.; Poluzzi, E.; Cavalli, A.; Recanatini, M.; Montanaro, N. (2002). «Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview». Drug Safety 25 (4): 263-286. PMID 11994029. doi:10.2165/00002018-200225040-00004.
Recanatini, M.; Poluzzi, E.; Masetti, M.; Cavalli, A.; De Ponti, F. (2005). «QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development». Medicinal Research Reviews 25 (2): 133-166. PMID 15389727. doi:10.1002/med.20019.
Raschi, E.; Vasina, V.; Poluzzi, E.; De Ponti, F. (2008). «The hERG K+ channel: target and antitarget strategies in drug development». Pharmacological Research 57 (3): 181-195. PMID 18329284. doi:10.1016/j.phrs.2008.01.009.
Raschi, E.; Ceccarini, L.; De Ponti, F.; Recanatini, M. (2009). «hERG-related drug toxicity and models for predicting hERG liability and QT prolongation». Expert Opinion on Drug Metabolism & Toxicology 5 (9): 1005-1021. PMID 19572824. doi:10.1517/17425250903055070.
Huang, X.; Setola, V.; Yadav, P.; Allen, J.; Rogan, S.; Hanson, B.; Revankar, C.; Robers, M. et al. (2009). «Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment». Molecular Pharmacology 76 (4): 710-722. PMC 2769050. PMID 19570945. doi:10.1124/mol.109.058057.
Bhattacharyya, S.; Schapira, A. H.; Mikhailidis, D. P.; Davar, J. (2009). «Drug-induced fibrotic valvular heart disease». The Lancet 374 (9689): 577-85. PMID 19683643. doi:10.1016/S0140-6736(09)60252-X.
«Psychedelics». Pharmacol. Rev. 68 (2): 264-355. 2016. PMC 4813425. PMID 26841800. doi:10.1124/pr.115.011478.
«Neuropsychiatric Effects of HIV Antiviral Medications». Drug Saf 39 (10): 945-57. 2016. PMID 27534750. doi:10.1007/s40264-016-0440-y.
«The HIV antiretroviral drug efavirenz has LSD-like properties». Neuropsychopharmacology 38 (12): 2373-84. 2013. PMC 3799056. PMID 23702798. doi:10.1038/npp.2013.135.

federalregister.gov (Global: 2,474^th place; Spanish: 9,675^th place)

«Schedules of Controlled Substances: Placement of Lorcaserin into Schedule IV». 8 de mayo de 2013.

nih.gov (Global: 4^th place; Spanish: 4^th place)

ncbi.nlm.nih.gov

Klabunde, T.; Evers, A. (2005). «GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects». ChemBioChem: A European Journal of Chemical Biology 6 (5): 876-889. PMID 15791686. doi:10.1002/cbic.200400369.
Price, D.; Blagg, J.; Jones, L.; Greene, N.; Wager, T. (2009). «Physicochemical drug properties associated with in vivo toxicological outcomes: a review». Expert Opinion on Drug Metabolism & Toxicology 5 (8): 921-931. PMID 19519283. doi:10.1517/17425250903042318.
De Ponti, F.; Poluzzi, E.; Cavalli, A.; Recanatini, M.; Montanaro, N. (2002). «Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview». Drug Safety 25 (4): 263-286. PMID 11994029. doi:10.2165/00002018-200225040-00004.
Recanatini, M.; Poluzzi, E.; Masetti, M.; Cavalli, A.; De Ponti, F. (2005). «QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development». Medicinal Research Reviews 25 (2): 133-166. PMID 15389727. doi:10.1002/med.20019.
Raschi, E.; Vasina, V.; Poluzzi, E.; De Ponti, F. (2008). «The hERG K+ channel: target and antitarget strategies in drug development». Pharmacological Research 57 (3): 181-195. PMID 18329284. doi:10.1016/j.phrs.2008.01.009.
Raschi, E.; Ceccarini, L.; De Ponti, F.; Recanatini, M. (2009). «hERG-related drug toxicity and models for predicting hERG liability and QT prolongation». Expert Opinion on Drug Metabolism & Toxicology 5 (9): 1005-1021. PMID 19572824. doi:10.1517/17425250903055070.
Huang, X.; Setola, V.; Yadav, P.; Allen, J.; Rogan, S.; Hanson, B.; Revankar, C.; Robers, M. et al. (2009). «Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment». Molecular Pharmacology 76 (4): 710-722. PMC 2769050. PMID 19570945. doi:10.1124/mol.109.058057.
Bhattacharyya, S.; Schapira, A. H.; Mikhailidis, D. P.; Davar, J. (2009). «Drug-induced fibrotic valvular heart disease». The Lancet 374 (9689): 577-85. PMID 19683643. doi:10.1016/S0140-6736(09)60252-X.
«Psychedelics». Pharmacol. Rev. 68 (2): 264-355. 2016. PMC 4813425. PMID 26841800. doi:10.1124/pr.115.011478.
«Neuropsychiatric Effects of HIV Antiviral Medications». Drug Saf 39 (10): 945-57. 2016. PMID 27534750. doi:10.1007/s40264-016-0440-y.
«The HIV antiretroviral drug efavirenz has LSD-like properties». Neuropsychopharmacology 38 (12): 2373-84. 2013. PMC 3799056. PMID 23702798. doi:10.1038/npp.2013.135.

Antiobjetivo (Spanish Wikipedia)

doi.org (Global: 2nd place; Spanish: 2nd place)

dx.doi.org

federalregister.gov (Global: 2,474th place; Spanish: 9,675th place)

nih.gov (Global: 4th place; Spanish: 4th place)

ncbi.nlm.nih.gov

doi.org (Global: 2^nd place; Spanish: 2^nd place)

federalregister.gov (Global: 2,474^th place; Spanish: 9,675^th place)

nih.gov (Global: 4^th place; Spanish: 4^th place)